NCT04107298已完成不适用
A Prospective, Multi-Center, Single-Arm, Feasibility Study to Assess the Safety and Performance WIth the SUNDANCE™ DruG Coated Balloon for the Treatment of De Novo or Restenotic Lesions in Infra-Popliteal Arteries
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 8
- 主要终点
- Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death
研究概览
简要总结
To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.
详细描述
SWING is a prospective, multi-center, single-arm, feasibility study to assess the safety and performance of the Sundance™ drug coated balloon for the treatment of de novo or restenotic lesions in infra-popliteal Arteries. Approximately 35 subjects will be treated at up to 8 sites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria
- •Subject is ≥18 years.
- •Subject has target limb Rutherford classification 4 or
- •Rutherford classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (i.e., no more than 7 Rutherford class 3 subjects may be enrolled in the study).
- •Subject has provided written informed consent and is willing to comply with study follow-up requirements.
排除标准
- •Subject has acute limb ischemia.
- •Subject underwent intervention involving the target vessel (not a proximal inflow vessel) within the previous 90 days.
- •Subject previously underwent PTA of the target lesion vessel using a DCB or DES.
- •Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure.
- •Subjects with heel gangrene, deep heel ulcers, osteomyelitis of tarsal or metatarsal bones (which extends beyond the metatarsal head immediately adjacent to the metatarso-phalangeal joint), and subjects with exposed vital structures (e.g., medial or lateral malleolus).
- •Subjects requiring pedal angioplasty.
- •Subjects that are non-ambulatory and confined to bed.
- •Women who are pregnant, breast-feeding or intend to become pregnant or men who intend to father children during the time of the study.
- •Subject has history of Class 3 (and above) congestive heart failure (CHF) in past 6 months.
- •Subject has life expectancy less than 12 months.
- •Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
- •Subject has known hypersensitivity to sirolimus
- •Subject has a known contraindication to the intended concomitant medications.
- •Subject is allergic to ALL antiplatelet treatments.
- •Subject has impaired renal function (i.e. serum creatinine level ≥2.5 mg/dL or ≥221 µmol/L).
- •Subject had major limb amputation on the affected side in last year or has planned major limb amputation.
- •Subject is receiving immunosuppressant therapy.
- •Subject has known or suspected active infection at the time of the index procedure.
- •Subject has platelet count <100,000/mm3 or >700,000/mm
- •Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure.
- •Subject is diagnosed with coagulopathy or other disorders which are contraindications for treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
- •Subject has history of stroke within the past 3 months.
- •Subject has a history of myocardial infarction within the past 30 days.
- •Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
- •Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol.
- •Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
- •Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure.
- •Subject had previous bypass surgery of the target lesion.
- •Subject had previously implanted stent in target lesion.
- •Subject had previous treatment of the target vessel with thrombolysis or surgery.
- •Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
- •Angiographic Inclusion Criteria
- •The target lesion/vessel must meet all of the following angiographic criteria for the subject to participate in the trial:
- •De novo lesion(s) or non-stented restenotic lesion
- •Target lesion location starts at the P3 segment and terminates at 1cm above the ankle. Note: Isolated P3 lesion is not allowed. If a lesion starts in the P3 segment, it must continue into the infrapopliteal.
- •Target vessel diameter ≥2 mm and ≤4 mm, based on visual estimation.
- •Target lesion must have angiographic evidence of ≥70% stenosis by operator visual estimate.
- •Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion. Use of re-entry/crossing devices is not allowed. Crossing may be performed retrograde, but treatment must be performed antegrade.
- •Uncomplicated: Upon visual inspection, no occurrence of embolization, perforation, or occurrence of flow-limiting dissection.
- •Target lesion(s) must be ≤230 mm in total lesion(s) length by operator visual estimate. A maximum of two lesions may be treated. The two lesions may be in one infrapopliteal vessel or in two distinct infrapopliteal vessels. Note: Tandem lesions may be considered a single lesion if they are separated by ≤30 mm.
- •After pre-dilatation, the target lesion has ≤70% residual stenosis, absence of a flow limiting dissection (Grade D or greater) and treatable with available device matrix.
- •A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography.
- •At least one patent native outflow artery to the ankle or foot distal to the lesion being treated, free from significant stenosis (≥50% stenosis) as confirmed by angiography.
- •Angiographic Exclusion Criteria
- •Aneurysm in the target vessel or proximal inflow artery.
- •Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length ≥15 cm.
- •Significant stenosis (≥ 50%) in inflow lesion or occlusion in the ipsilateral iliac, SFA, popliteal arteries left untreated.
- •Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, or re-entry devices.
- •Significant target vessel tortuosity or other parameters prohibiting access to the target lesion.
- •Presence of thrombus in the target vessel.
研究组 & 干预措施
SUNDANCE™ Drug Coated Balloon
Experimental
SUNDANCE™ Drug Coated Balloon
干预措施: SUNDANCE™ Drug Coated Balloon (Device)
结局指标
主要结局
Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death
时间窗: 30 Days
MALE is defined as the composite of either major amputation or major re-intervention through 30 days of the index procedure. Major amputation is defined as limb amputation above the ankle. Major re-intervention is defined as the creation of new surgical bypass graft, the use of thrombectomy or thrombolysis, or major surgical graft revision such as a jump graft or an interposition graft.
Primary Efficacy Endpoint: Rate of Late Lumen Loss (LLL)
时间窗: 6 Months
LLL is assessed by quantitative vascular angiography (QVA). LLL is the difference between minimum lumen diameter (MLD) immediately after PTA and MLD at 6 months follow-up.
次要结局
- Rate of Technical Success(Acute/Periprocedural)
- Rate of Restenosis(6 Months or prior)
- Walking Impairment Questionnaire (WIQ)(30 Days, 6 Months, 12 Months, 24 Months)
- Major Adverse Event (MAE) rate(30 Days, 6 Months, 12 Months, 24 Months)
- Change in Rutherford-Becker Classification(30 Days, 6 Months, 12 Months, 24 Months)
- Rate of Device Success(Acute/Periprocedural)
- Rate of Procedure Success(Acute/Periprocedural)
- Amputation Free Survival(6 Months, 12 Months, 24 Months)
- EQ-5D(30 Days, 6 Months, 12 Months, 24 Months)
- Number of Participants with Primary Patency(30 Days, 6 Months, 12 Months, 24 Months)
- Hemodynamic outcomes(30 Days, 6 Months, 12 Months, 24 Months)
- Vascular Quality of Life Questionnaire (VascuQol)(30 Days, 6 Months, 12 Months, 24 Months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (AVess FIH)Hemodialysis Access FailureNCT03734679SurModics, Inc.12
已完成
不适用
A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal ArteriesFemoral Artery StenosisOcclusion of Popliteal ArteriesFemoral Artery OcclusionStenosis of Popliteal ArteriesNCT02720003C. R. Bard148
进行中（未招募）
不适用
BSD-10CH TDCS for Upper Limb Function Improvement in Stroke Patients: a Randomized Clinical TrialTDCSStrokeNCT06740604Pusan National University Yangsan Hospital60
已完成
不适用
ADvance DBS-f in Patients With Mild Probable Alzheimer's DiseaseAlzheimer DiseaseNCT01608061Functional Neuromodulation Ltd42
已完成
不适用
A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory GlaucomaGlaucomaNCT05131087New World Medical, Inc.30